Immunome Inc (IMNM) is a Healthcare · Biotechnology company listed on NASDAQ. Price $23.75 (-0.75%), Market cap $2.36B, 52-week low–high $7.92 ~ $26.97.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immu
Financial statements, price targets, institutional (13F) holdings and related news for Immunome Inc are updated in real time on BlackAll Trade.
Immunome Inc trades at $23.75 (-0.75%). Real-time quotes and charts are available on BlackAll Trade.
Immunome Inc has a market cap of about $2.36B.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United S